Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12

Immunology

Volumn 115, Issue 4, 2005, Pages 451-461

  Homma, Sadamu ^a   Komita, Hideo ^a   Sagawa, Yukiko ^a   Ohno, Tsuneya ^a   Toda, Gotaro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer vaccine; CD4+ cytotoxic T lymphocytes; Dendritic cells; Hepatocellular carcinoma; Interleukin 12

Indexed keywords

CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CONCANAMYCIN A; DENDRITIC CELL VACCINE; FAS ANTIBODY; FAS LIGAND; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PERFORIN; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTE DEPLETION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIVER NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PORE FORMING CYTOTOXIC PROTEINS; SPLEEN;

EID: 22744442701     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2005.02179.x     Document Type: Article

References (43)

1. Kershaw MH, Trapani JA, Smyth MJ. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 1995; 2:173-81.
2. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapins AD, Sotiriadou R, Papamichail M. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000; 164:3902-12.
3. Marzo AL, Kinnear BF, Lake RA, Frellinger JJ, Collins EJ, Robinson BW. Tumor-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J Immunol 2000; 165:6047-55.
4. Wang RF. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 2002; 188:65-80.
5. Schultz ES, Lethe B, Cambiaso CL et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 2000; 60:6272-5.
6. Echchakir H, Bagot M, Dorothee G et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 2000; 115:74-80.
7. Eljaafari A, Farre A, Dupperrier K, Even J, Vie H, Michallet M, Souillet G. Generation of helper and cytotoxic CD4+ T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells. Transplantation 2001; 71:1449-55.
8. Grogg D, Hahn S, Erb P. CD4+ T cell-mediated killing of major histochompatibility complex class II-positive antigen-presenting cells (APC). III. CD4+ cytotoxic T cells induce apoptosis of APC. Eur J Immunol 1992; 22:267-72.
9. Ottenhoff TH, Mutis T. Specific killing of cytotoxic T cells and antigen presenting cells by CD4+ cytotoxic T cell clones. A novel potentially immunoregulatory T-T cell interaction in man. J Exp Med 1990; 171:2011-24.
10. Cho HI, Kim HJ, Oh ST, Kim TG. In vitro induction of carcino-embryonic antigen (CEA)-specific cyotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 2003; 22:224-36.
11. Tanaka Y, Takahashi T, Nieda M et al. Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p 190 minor bcr-abl fusion peptide. Leuk Res 2002; 26:317-21.
12. Porakishvili N, Roschupkina T, Kalber T, Jewell AP, Patterson K, Yong K, Lydyard PM. Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukemia (B-CLL). Clin Exp Immunol 2001; 126:29-36.
13. Guy K, Krajewski AS, Dewar AE. Expression of MHC class II antigens in human B-cell leukemia and non-Hodgkin's lymphoma. Br J Cancer 1986; 53:161-73.
14. Ruiz-Cabello F, Klein E, Garrido F. MHC antigens on human tumors. Immunol Letter 1991; 29:181-9.
15. Porakishvili N, Kardava L, Jewell AP, Yong K, Glennie MJ, Akbar A. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Heamatologica 2004; 89:435-43.
16. Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152:1127-33.
17. Dorothee G, Vergnon I, Menez J, Echchakir H, Grunenwald D, Kubin M. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and mediated cytotoxicity. J Immunol 2002; 169:809-17.
18. Lu X, Kallinteris NL, Li J et al. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol Immunother 2003; 52:592-8.
19. Hillman GG, Kallinteris LN, Lu X et al. Turning tumor cells in situ T-helper cell-stimulating MHC-class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Cancer Treat Rev 2004; 30:281-90.
20. Kasper HU, Drebber U, Zur Hausen A, Stippel D, Dienes HP, Dries V. Dominance of CD4+ alpha/beta T-cells and inferior role of innate immune reaction in liver metastases. Anticancer Res 2003; 23:3175-81.
21. Nakakubo Y, Miyamoto M, Cho Y et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89:1736-42.
22. Wakabayashi O, Yamazaki K, Oizumi S et al. CD4 (+) T cells in cancer stroma, not CD8(+) T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94:1003-9.
23. Ladanyi A, Somlai B, Gilde K, Fejos Z, Gaudi I, Timar J. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 15:521-30.
24. Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S. Tumor-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004; 91:469-75.
25. Marincola FM, Jaffee EM, Micklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
26. Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 2003; 4:525-36.
27. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64:275-90.
28. Ohno S, Suzuki N, Ohno Y, Inagawa H, Soma G, Inoue M. Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res 2003; 23:4395-409.
29. National Academy of Sciences. Guide for the Care and Use of Laboratory Animals. NIH publication. National Institutes of Health, 1985.
30. Patek PQ, Collins JL, Cohn M. Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis. Nature 1978; 6:510-1.
31. Inaba K, Inaba M, Romani R et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony stimulation factor. J Exp Med 1992; 176:1693-702.
32. Yamaguchi Y, Tsumura H, Miwa M, Inaba K. Contrasting effects of TGF-β and TNF-α on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cell 1997; 15:144-53.
33. Gong I, Chen D, Kashiwaba M, Kufe D. Induction of antitumoractivity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558-61.
34. Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive antitumoractivity against hepatocellar carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 2001; 36:764-71.
35. Iinuma T, Homma S, Noda T, Kufe D, Ohno T, Toda G. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene. J Clin Invest 2004; 113:1307-17.
36. Irie M, Homma S, Komita H, Zeniya M, Kufe D, Ohno T, Toda G. Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCrj mice. Int J Cancer 2004; 111:238-45.
37. Igarashi O, Yamane H, Imajoh-Ohmi S, Nariuchi H. IL-12 receptor (IL-12R) expression and accumulation of IL-12Rβ1 and IL-12Rβ2 mRNA in CD4+ T cells by costimulation with B7-2 molecules. J Immunol 1998; 160:1638-46.
38. Mumberg D, Monach PA, Waderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci USA 1999; 96:8633-8.
39. Casares N, Arribillaga L, Sarobe P et al. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003; 171:5931-9.
40. Liu CC, Persechini PM, Young JD. Perforin and lymphocyte-mediated cytolysis. Immunol Rev 1995; 146:145-75.
41. Cohen DA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S. CD4+ T cells in adaptive immunotherapy and indirect mechanism of tumor rejection. Crit Rev Immunol 2000; 20:17-56.
42. Shurin MR. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996; 43:158-64.
43. Tatsumi T, Takehara T, Kanto T et al. Administration of interleukin-12 enhances the therapeutic effect of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 2001; 61:7563-7.